The Lung Cancer Drug Nobody Saw Coming Just Won Again
Zipalertinib just scored its second Phase 3 win in one of lung cancer's most drug-resistant mutations. With J&J's Rybrevant as the reigning champ and an FDA decision date already on the calendar, this oral pill could reshape how doctors treat EGFR exon 20 insertion NSCLC.
A Mutation That Laughs at Most Drugs
Imagine a lock that's been jammed shut. You've got a ring full of keys, but none of them fit because someone stuffed extra metal into the keyhole. That's essentially what EGFR exon 20 insertion mutations do to lung cancer treatment.
These mutations account for a small but stubborn slice of non-small cell lung cancer (NSCLC). They warp the shape of a protein on cancer cells just enough that most targeted drugs can't latch on. For years, patients with this mutation were stuck with chemotherapy and its modest results.
So when a drug actually cracks that jammed lock, people pay attention. And zipalertinib just did it for the second time in a row.
Two for Two
On August 12, Taiho Pharmaceutical and Cullinan Therapeutics announced that their Phase 3 trial called REZILIENT3 hit its primary endpoint. The study tested zipalertinib plus chemotherapy against chemotherapy alone in 285 patients who had never been treated for their advanced EGFR exon 20 insertion lung cancer. At a planned interim look, an independent monitoring committee saw enough of a difference in progression-free survival (how long patients lived without their cancer worsening) that they recommended unblinding the study.
The companies haven't released the exact numbers yet; those are being saved for a major medical conference. But the word "statistically significant and clinically meaningful" doesn't get thrown around lightly in oncology press releases. This is the kind of language that precedes regulatory filings.
This win follows earlier results from the REZILIENT1 study, which showed a confirmed response rate of 35.2% and responses lasting a median of 8.8 months in patients who had already been through other treatments. Winning in pretreated patients is one thing. Winning in the first-line setting, where you're competing head-to-head against the current standard of care, is a much bigger deal.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A quick biology lesson that won't put you to sleep. EGFR (epidermal growth factor receptor) is a protein on the surface of cells that tells them to grow. In many lung cancers, EGFR is mutated, which means it's stuck in the "on" position, fueling tumor growth. Drugs called TKIs (tyrosine kinase inhibitors) block that signal.
But exon 20 insertion mutations are the rebellious teenager of the EGFR family. They cram extra genetic material into a specific region of the gene, physically narrowing the pocket where most TKIs need to bind. It's like trying to park an SUV in a compact-car spot.
Zipalertinib was designed from the ground up to fit that tighter space. It locks on permanently (that's the "irreversible" part) by bonding to a specific spot called Cys797 inside the kinase domain. Crucially, it does this without hammering normal, non-mutated EGFR nearly as hard, which is why its side-effect profile has looked manageable so far.
The Heavyweight It's Coming For
If you follow EGFR exon 20 insertion lung cancer (and honestly, who doesn't at parties?), you know the current first-line champ is amivantamab (brand name Rybrevant), made by Johnson & Johnson. After the Phase 3 PAPILLON trial, amivantamab plus chemotherapy became the go-to combo for newly diagnosed patients.
But amivantamab is an antibody-based therapy, not a pill. That distinction matters. Antibody treatments can be harder to administer and tougher to tolerate for some patients, particularly those who are frail or need rapid symptom control. A selective oral TKI that works in the same setting could be a game-changer for oncologists looking for alternatives.
There's also the ghost of mobocertinib, which was once a rising star in this space before its Phase 3 trial flopped and its indication was pulled. That exit left a gap in the market and reminded everyone how hard this mutation is to treat. Meanwhile, sunvozertinib picked up an accelerated FDA approval in 2025, but only for patients whose cancer progressed after platinum-based chemo. It's a second-line option, not a first-line threat.
Zipalertinib is positioning itself to compete in both settings.
Follow the Money
The partnership between Taiho and Cullinan is structured to make both companies very motivated. They split U.S. development costs 50/50 and would share U.S. profits the same way. Outside the U.S., Taiho takes the wheel entirely.
For Cullinan, the financial upside is stacked like a layer cake. The company stands to earn $30 million if zipalertinib wins U.S. approval for previously treated patients, and up to $130 million in total U.S. regulatory milestone payments. That second milestone just got a lot more realistic.
Wall Street noticed. BTIG analyst Kaveri Pohlman reiterated a Buy rating on Cullinan with a $20 price target, while JonesTrading initiated coverage with a Buy and a $22 target. Both firms pointed to the expanding market opportunity, especially now that the first-line data looks strong. The stock has historically moved sharply on zipalertinib milestones, and this one is the biggest yet.
The Road From Here
Zipalertinib already has an NDA accepted by the FDA for the post-chemo setting, with a decision date of February 27, 2027. Taiho and Cullinan said they plan to discuss the new first-line data with regulators and pursue approval for that indication too.
If both approvals come through, zipalertinib would be the first oral TKI available across multiple lines of therapy for EGFR exon 20 insertion lung cancer. That's a compelling commercial story in a niche where existing treatments still leave enormous gaps in long-term disease control.
The full REZILIENT3 data will tell us how big the PFS improvement really is, whether certain patient subgroups benefited more, and how the safety profile compares to amivantamab-based regimens. Those details will determine whether zipalertinib becomes a true standard of care or just another option.
But two Phase 3 wins is two Phase 3 wins. In a mutation that's made fools of other drugs, zipalertinib keeps finding a way to fit.
Deals & M&A5 min read
PTC Just Bought a Gene Therapy Out of Bankruptcy. It Might Be Brilliant.
PTC Therapeutics just scooped up a near-approval Fabry disease gene therapy from Sangamo's bankruptcy auction for $211 million. It's either the deal of the year or a cautionary tale waiting to happen.
